BS-104 is a targeted anticancer drug and an orally administered, multi-targeted small-molecule tyrosine kinase inhibitor. It can be developed as a generic or an incrementally modified drug (IMD) of Nexavar®. By using NUFS™ technology, BS-104 can be launched earlier without the patent infringements of the original drug’s patents related to both crystal form and formulation. In addition, BS-104 can reduce adverse effects due to unabsorbed sorafenib particles present in the gut by increasing bioavailability and reducing the dose of BS-104 compared to Nexavar®.